Remedy Robotics raises $62M to take its remote endovascular robot toward FDA review

Remedy Robotics raises $62M to take its remote endovascular robot toward FDA review

Latest Medtech News


Remedy Robotics, a San Francisco company developing the N1 robotic system for endovascular procedures, has raised a $62 million Series B led by DCVC. New investors include the University of California’s investment office, Skip Capital and Hostplus, and existing backers Blackbird, Divergent Capital, Tony Fadell and KdT Ventures also took part.

As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.

The funding will support a planned pivotal trial of N1 across the University of California network, which the company has worked with since 2021, ahead of a regulatory submission to the FDA. N1 is an AI-enabled platform that can be installed in a catheterization lab. Remedy says it lets specialists control tool movement and device deployment from a remote location while viewing live images from the procedure site. In October 2025, the company reported completing what it calls the world’s first remote neurointerventional procedures with the system, on a patient across Toronto from where the system was located. N1 is still in development and is not available for sale or clinical use anywhere.

For Remedy, the round funds the evidence needed to move from demonstration to regulatory review. CEO David Bell said access to endovascular intervention is limited to a small number of hospitals, and that N1 aims to bring quality intervention to patients “regardless of geography.”

For the broader MedTech space, it’s another sizable raise for endovascular robotics, alongside Mosaic Intelligence Labs’ $47 million seed and Laza Medical’s round this month.

Go Back

We'd love to hear what you're building